ANTITUSSIVE Drug Patent Profile
✉ Email this page to a colleague
When do Antitussive patents expire, and what generic alternatives are available?
Antitussive is a drug marketed by Perrigo and is included in one NDA.
The generic ingredient in ANTITUSSIVE is diphenhydramine hydrochloride. There is one drug master file entry for this compound. Twenty suppliers are listed for this compound. Additional details are available on the diphenhydramine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Antitussive
A generic version of ANTITUSSIVE was approved as diphenhydramine hydrochloride by WEST-WARD PHARMS INT on December 31st, 1969.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ANTITUSSIVE?
- What are the global sales for ANTITUSSIVE?
- What is Average Wholesale Price for ANTITUSSIVE?
Summary for ANTITUSSIVE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 115 |
| Clinical Trials: | 40 |
| Patent Applications: | 2,411 |
| DailyMed Link: | ANTITUSSIVE at DailyMed |
Recent Clinical Trials for ANTITUSSIVE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sakarya University | NA |
| Pontificia Universidad Catolica de Chile | PHASE4 |
| UC CHRISTUS | PHASE4 |
US Patents and Regulatory Information for ANTITUSSIVE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perrigo | ANTITUSSIVE | diphenhydramine hydrochloride | SYRUP;ORAL | 071292-001 | Apr 10, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
